Finding a surface protein can help explain how an antibody drug reaches a tumor. The amount of protein measured in a biopsy does not describe every step needed for the treatment to work.
Antigen measurement, drug uptake, intracellular processing and payload sensitivity describe different parts of antibody-drug conjugate activity. DAISY, a single-arm phase 2 study, examined trastuzumab deruxtecan across HER2 expression cohorts and found activity in more than one expression category. That study does not establish a universal expression cutoff or a comparative treatment effect in every cohort. A biomarker rule needs evidence for the particular drug, assay, disease and setting.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Prognostic and predictive biomarkers, Evidence from measurement to patient benefit, Biomarker.
Shares Antibody internalization and intracellular trafficking, Evidence from measurement to patient benefit, Antibody-drug conjugate (ADC).
Shares Antibody internalization and intracellular trafficking, Evidence from measurement to patient benefit.
Shares Evidence from measurement to patient benefit, Biomarker.
Shares Binding-site barrier in tumor delivery, Evidence from measurement to patient benefit.
Shares Biomarker, Immunohistochemistry (IHC), Antibody-drug conjugate (ADC).
Shares Evidence from measurement to patient benefit, Biomarker.
Shares Antibody internalization and intracellular trafficking, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/